Develops mRNA-based vaccines and therapeutics for infectious diseases and cancer.
CureVac N.V., headquartered in Tübingen, Germany, is a clinical-stage biopharmaceutical company pioneering the development of transformative medicines based on messenger ribonucleic acid (mRNA) technology. This innovative approach aims to revolutionize medical treatments by leveraging the body's own cellular mechanisms to combat diseases.
At the forefront of CureVac's diverse pipeline are prophylactic vaccines designed to prevent infectious diseases. This includes CV2CoV, an mRNA-based vaccine candidate currently undergoing Phase 1 clinical trials targeting SARS-CoV-2, the virus responsible for COVID-19. The company's extensive vaccine portfolio also features CV7202, which completed Phase 1 trials for rabies virus glycoprotein, and CVSQIV, in Phase 1 trials for influenza prevention. CureVac is additionally advancing vaccines for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and a universal influenza vaccine.
Beyond infectious diseases, CureVac is pioneering RNA-based cancer immunotherapies. Notably, CV8102 is undergoing Phase 1 clinical trials for treating cutaneous melanoma, adenoid cystic carcinoma, and various squamous cell cancers of the skin, head, and neck. Founded in 2000, CureVac continues to drive innovation in mRNA technology, aiming to address global health challenges through its commitment to advancing therapeutic solutions.